相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A
Wayne L. Furman et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group
Ami Desai et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children?s Oncology Group
Pooja Hingorani et al.
EUROPEAN JOURNAL OF CANCER (2022)
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group
Rajen Mody et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Natural killer cells in cancer biology and therapy
Song-Yang Wu et al.
MOLECULAR CANCER (2020)
Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab
Amy K. Erbe et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
CD161 Defines a Functionally Distinct Subset of Pro-Inflammatory Natural Killer Cells
Ayako Kurioka et al.
FRONTIERS IN IMMUNOLOGY (2018)
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Amy K. Erbe et al.
CLINICAL CANCER RESEARCH (2018)
FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma
Amy K. Erbe et al.
CLINICAL CANCER RESEARCH (2017)
Irinotecan-temozolomide with temsirolimus or dinutuximab Crosstafark in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
Rajen Mody et al.
LANCET ONCOLOGY (2017)
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy
Amy K. Erbe et al.
FRONTIERS IN IMMUNOLOGY (2017)
Natural killer cell receptors: alterations and therapeutic targeting in malignancies
Gordana Konjevic et al.
IMMUNOLOGIC RESEARCH (2016)
Neuroblastoma patients with high-affinity FCGR2A,-3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival
Nikolai Siebert et al.
OncoImmunology (2016)
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles et al.
NATURE MEDICINE (2015)
Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients
Michaela Semeraro et al.
Science Translational Medicine (2015)
NK Cell Tolerance of Self-Specific Activating Receptor KIR2DS1 in Individuals with Cognate HLA-C2 Ligand
Gianfranco Pittari et al.
JOURNAL OF IMMUNOLOGY (2013)
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
Nidale Tarek et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
Nicolas F. Delahaye et al.
NATURE MEDICINE (2011)
Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy
David C. Delgado et al.
CANCER RESEARCH (2010)
KIR and HLA Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma
Jeffrey M. Venstrom et al.
CLINICAL CANCER RESEARCH (2009)
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor
NKV Cheung et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
分享论文
